Intravenous methylprednisolone for multiple sclerosis in relapse.

Area of Science:

• Neurology
• Clinical Pharmacology

Background:

• Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Acute relapses of MS require effective treatment to manage symptoms and recovery.
• Adrenocorticotropic hormone (ACTH) has been a standard treatment for MS relapses.

Purpose of the Study:

• To compare the efficacy of intravenous methylprednisolone with a standard ACTH regimen for treating acute multiple sclerosis relapses.
• To evaluate the speed of clinical improvement and long-term benefits of both treatments.

Main Methods:

• A randomized controlled trial was conducted.
• Patients received either methylprednisolone (1 g intravenously daily for 7 days) or a standard ACTH regimen.
• Clinical improvement was assessed at multiple time points, including a 3-month follow-up.

Main Results:

• Methylprednisolone demonstrated a significantly faster rate of clinical improvement compared to ACTH.
• No significant difference in long-term benefits was observed between the two treatment groups at the 3-month mark.
• Both treatments aimed to reduce inflammation during acute MS exacerbations.

Conclusions:

• Intravenous methylprednisolone offers a faster initial recovery for patients experiencing acute multiple sclerosis relapses.
• While providing rapid symptom relief, methylprednisolone does not appear to offer superior long-term outcomes over ACTH at 3 months.
• Intravenous methylprednisolone is a viable option for managing acute MS relapses, particularly when rapid symptom improvement is desired.